Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Less-expensive diuretics found superior in treatment of hypertension

17.12.2002


A major clinical trial of blood pressure medications has concluded that an inexpensive diuretic (water pill) is more effective in treating high blood pressure and preventing cardiovascular disease than newer more expensive medications.

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), conducted from February 1994 though March 2002, compared the drugs for use in starting treatment for high blood pressure.

"The preferred drug is the diuretic for three reasons. It provides better control of hypertension; it reduces complications from hypertension--particularly heart failure-- more effectively; and it is 10 to 20 times less expensive than the other drugs used in the trial," said Curt Furberg, M.D., Ph.D., of Wake Forest University Baptist Medical Center, chairman of the study’s steering committee.



ALLHAT is the largest study ever to compare different types of hypertension drugs. It included more than 33,000 participants age 55 years or older at 623 clinical sites in North America. All the patients had hypertension and at least one other coronary heart disease risk factor. Approximately 50 percent of the participants were women and 35 percent were African-American.

"The bottom line is ALLHAT has shown that it matters which drug you use to control hypertension," said Furberg.

Participants were randomly assigned to receive the diuretic chlorthalidone, amlodipine (a calcium channel blocker sold under the name Norvasc) or lisinopril, (an angiotensin-converting enzyme (ACE) inhibitor sold under the names Prinivil and Zestril.)

In 2000, another drug used in the trial, doxazosin (an alpha-blocker sold under the name Cardura) was pulled from the trial because it was determined early in ALLHAT that it was not as effective as the less expensive diuretic medication.

The study does not recommend that patients stop taking their medication if they are using a drug other than a diuretic. However they are encouraged to speak with their physicians about adding or switching to a diuretic for their treatment.

ALLHAT’s findings indicate that most patients will need more than one drug to adequately control their blood pressure and one of the drugs should be a diuretic. The National Heart, Lung and Blood Institute, part of the National Institutes of Health, supported the study.


Contact: Jim Steele, jsteele@wfubmc.edu, Jonnie Rohrer, ´jrohrer@wfubmc.edu, Karen Richardson, krchrdsn@wfubmc.edu or Barbara Hahn, bhahn@wfubmc.edu, 716-4587.

Jim Steele | EurekAlert!
Further information:
http://www.wfubmc.edu/

More articles from Health and Medicine:

nachricht Purdue cancer identity technology makes it easier to find a tumor's 'address'
16.11.2018 | Purdue University

nachricht Microgel powder fights infection and helps wounds heal
14.11.2018 | Michigan Technological University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: UNH scientists help provide first-ever views of elusive energy explosion

Researchers at the University of New Hampshire have captured a difficult-to-view singular event involving "magnetic reconnection"--the process by which sparse particles and energy around Earth collide producing a quick but mighty explosion--in the Earth's magnetotail, the magnetic environment that trails behind the planet.

Magnetic reconnection has remained a bit of a mystery to scientists. They know it exists and have documented the effects that the energy explosions can...

Im Focus: A Chip with Blood Vessels

Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.

Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...

Im Focus: A Leap Into Quantum Technology

Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.

In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...

Im Focus: Research icebreaker Polarstern begins the Antarctic season

What does it look like below the ice shelf of the calved massive iceberg A68?

On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.

Im Focus: Penn engineers develop ultrathin, ultralight 'nanocardboard'

When choosing materials to make something, trade-offs need to be made between a host of properties, such as thickness, stiffness and weight. Depending on the application in question, finding just the right balance is the difference between success and failure

Now, a team of Penn Engineers has demonstrated a new material they call "nanocardboard," an ultrathin equivalent of corrugated paper cardboard. A square...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

“3rd Conference on Laser Polishing – LaP 2018” Attracts International Experts and Users

09.11.2018 | Event News

On the brain’s ability to find the right direction

06.11.2018 | Event News

European Space Talks: Weltraumschrott – eine Gefahr für die Gesellschaft?

23.10.2018 | Event News

 
Latest News

Purdue cancer identity technology makes it easier to find a tumor's 'address'

16.11.2018 | Health and Medicine

Good preparation is half the digestion

16.11.2018 | Life Sciences

Microscope measures muscle weakness

16.11.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>